Psychedelic Institute Project
https://psychedelicmentalhealth.net/spotlight-n-n-dimethyltryptamine-elicits-antidepressant-and-anxiolytic-effects-in-helpless-mice-a-comparative-study-with-s-ketamine-da-sousa-silva-et-al-2026/ Spotlight: N,N-dimethyltryptamine elicits antidepressant and anxiolytic effects in helpless mice: a comparative study with S-ketamine (da Sousa-Silva, et al, 2026)
#DMT compared with #ketamine variant, #esketamine in mice. #depression #anxiety #psychedelics #psychedelic #psychedelicresearch
Cognitive Effects of Esketamine in Treatment-Resistant Depression: A Systematic Review - PubMed
Current evidence, albeit limited, suggests that esketamine appears to be cognitively safe in adults with treatment-resistant depression and may confer selective improvements, particularly in attention and processing speed, with more variable benefits in memory and executive functioning over sustaine …
Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study (Reif, et al, 2026) https://www.sciencedirect.com/science/article/pii/S0924977X26000428 #esketamine #spravato #psychedelics #depression #mentalhealth
Esketamine nasal spray for treatment-resistant depression: A retrospective multicenter real-world cohort study on effectiveness and suicidal outcomes (García-Jiménez, et al, 2026) https://pubmed.ncbi.nlm.nih.gov/41863095/ #esketamine #depression #spravato #suicides #mentalhealth #psychedelics "In real-world clinical setting, ESK NS produces progressive improvements in depressive symptoms and functioning that often consolidating beyond the induction phase, especially during optimization phase."
Esketamine nasal spray for treatment-resistant depression: A retrospective multicenter real-world cohort study on effectiveness and suicidal outcomes - PubMed
In real-world clinical setting, ESK NS produces progressive improvements in depressive symptoms and functioning that often consolidating beyond the induction phase, especially during optimization phase.
Ketamine as an NMDA-modulating therapy in bipolar disorder: rationale and evidence - PubMed
Ketamine and esketamine represent mechanistically novel and clinically effective treatments for bipolar depression. Their rapid antidepressant action and low switch liability distinguish them from traditional antidepressants. Esketamine, with its favorable tolerability and intranasal administration, …
Intranasal esketamine: real-world clinical practice in treatment-resistant depression and factors associated with treatment response (Baune, et al, 2026) https://link.springer.com/article/10.1186/s12888-026-07980-8 #mentalhealth #depression #esketamine #spravato #psychedelics #ketamine
J. R. DePriest 
:EA DATA. SF:Not for nothing, but after 30 years of trying to treat my treatment resistant depression, I'm a little over a month into Spravato (esketamine) treatment and it seems to be the only thing that's made a difference without intolerable side effects. In fact, I don't remember a time in my life ever when I've felt this way. The heaviness has lifted, not to be replaced by temporary mania or numbness, but a sort of objective clearness. I still have meltdowns and lapses, but they are growing fewer and I can better see them coming. I no longer feel trapped by them or inside of them. I feel more like I walk beside them. I hold their hand and try to navigate the world together. When I can. When I can. Sometimes they rush ahead. But my relationship with my depression is changing. We are equals now. I am learning to converse with it instead of letting it dictate the terms.
@PsychedelicInstitute https://mastodon.social/@PsychedelicInstitute/116216070749936835
#MentalHealth #TreatmentResistentDepression #TRD #Spravato #Esketamine
Industry sponsorship and research outcome (2017) Sponsorship of drug and device studies by the manufacturing company leads to more favorable efficacy results and conclusions than sponsorship by other sources. Our analyses suggest the existence of an industry bias that cannot be explained by standard 'Risk of bias' assessments. #ketamine #esketamine #spravato #psychedelics #psychiatry #nobillionaires https://pubmed.ncbi.nlm.nih.gov/28207928/
Industry sponsorship and research outcome - PubMed
Sponsorship of drug and device studies by the manufacturing company leads to more favorable efficacy results and conclusions than sponsorship by other sources. Our analyses suggest the existence of an industry bias that cannot be explained by standard 'Risk of bias' assessments.
https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.0040286 Ghost Management: How Much of the Medical Literature Is Shaped Behind the Scenes by the Pharmaceutical Industry? (Sismondo, 2007) #esketamine #ketamine #spravato #psychedelics #psychiatry drug companies pay for trials by contract research organizations (CROs), analyze the data in-house, have professionals write manuscripts, ask academics to serve as authors of those manuscripts, and pay communication companies to shepherd them through publication in the best journals.